{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T18:12:33Z","timestamp":1784225553232,"version":"3.55.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012479","name":"Weston Brain Institute","doi-asserted-by":"publisher","award":["RR192181"],"award-info":[{"award-number":["RR192181"]}],"id":[{"id":"10.13039\/100012479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Alzheimer\u2019s disease (AD) develops gradually, with significant neurodegeneration already present by the time clinical symptoms emerge. Since synapses are affected early in the disease, synaptic proteins are being investigated as potential markers of the prodromal stage. Using data and plasma samples provided by the Consortium for the early identification of Alzheimer\u2019s disease\u2014Quebec, we analyzed plasma levels of neuroligin (NLGN)-derived peptides in cognitively normal (CN) individuals and cognitively impaired (CI) individuals, including those with amnestic mild cognitive impairment and early-stage AD. Plasma levels of NLGN-derived peptides were assessed by quantifying tryptic peptides using liquid chromatography coupled with tandem mass spectrometry. Our findings show that levels of specific NLGN peptides were significantly elevated in CI compared to CN individuals. Receiver operating characteristic curve analysis revealed that some NLGN peptides could distinguish CI individuals. Furthermore, analysis based on mini-mental state examination scores revealed that specific plasma phosphorylated tau peptides were significantly and positively correlated with selected NLGN-derived peptides in more advanced stages of cognitive decline. These results support further investigation into synaptic NLGN-derived peptides in the blood as promising tools for monitoring the earliest stages of AD.<\/jats:p>","DOI":"10.1093\/gerona\/glag009","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:33:14Z","timestamp":1768566794000},"source":"Crossref","is-referenced-by-count":1,"title":["Differences in blood levels of neuroligin-derived peptides in a cohort for early detection of Alzheimer\u2019s disease"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1536-5083","authenticated-orcid":false,"given":"Milton G F","family":"Fernandes","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Physiology, Faculty of Medicine, Universit\u00e9 de Montr\u00e9al , Montreal, Qu\u00e9bec,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Pinard","sequence":"additional","affiliation":[{"name":"Translational Proteomics Laboratory, Institut de Recherches Cliniques de Montr\u00e9al , Montreal, Qu\u00e9bec,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esen","family":"Sokullu","sequence":"additional","affiliation":[{"name":"Translational Proteomics Laboratory, Institut de Recherches Cliniques de Montr\u00e9al , Montreal, Qu\u00e9bec,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyntia","family":"Tremblay","sequence":"additional","affiliation":[{"name":"Neuroscience Axis CHU de Qu\u00e9bec Research Center, Laval University , Quebec City, Qu\u00e9bec,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Gagnon","sequence":"additional","affiliation":[{"name":"Department of Psychology, Universit\u00e9 du Qu\u00e9bec \u00e0 Montr\u00e9al , Montreal, Qu\u00e9bec,","place":["Canada"]},{"name":"Centre for Advanced Research in Sleep Medicine, H\u00f4pital du Sacr\u00e9-Coeur de Montr\u00e9al, Centre int\u00e9gr\u00e9 universitaire de sant\u00e9 et de services sociaux du Nord de l\u2019\u00cele-de-Montr\u00e9al , Montreal, Qu\u00e9bec,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Calon","sequence":"additional","affiliation":[{"name":"Neuroscience Axis CHU de Qu\u00e9bec Research Center, Laval University , Quebec City, Qu\u00e9bec,","place":["Canada"]},{"name":"Faculty of Pharmacy, Laval University , Quebec City, Qu\u00e9bec,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Coulombe","sequence":"additional","affiliation":[{"name":"Translational Proteomics Laboratory, Institut de Recherches Cliniques de Montr\u00e9al , Montreal, Qu\u00e9bec,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Brouillette","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Physiology, Faculty of Medicine, Universit\u00e9 de Montr\u00e9al , Montreal, Qu\u00e9bec,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"2026040408410895000_glag009-B1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1017\/s1092852918001347","article-title":"State of the science on mild cognitive impairment (MCI)","volume":"24","author":"Anderson","year":"2019","journal-title":"CNS Spectr"},{"key":"2026040408410895000_glag009-B2","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1212\/WNL.0b013e318288690c","article-title":"Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI","volume":"80","author":"Vos","year":"2013","journal-title":"Neurology"},{"key":"2026040408410895000_glag009-B3","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.dadm.2019.07.003","article-title":"The consortium for the early identification of Alzheimer\u2019s disease\u2013Quebec (CIMA-Q)","volume":"11","author":"Belleville","year":"2019","journal-title":"Alz Dem Diag Ass Dis Mo"},{"key":"2026040408410895000_glag009-B4","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1126\/science.1074069","article-title":"Alzheimer\u2019s disease is a synaptic failure","volume":"298","author":"Selkoe","year":"2002","journal-title":"Science"},{"key":"2026040408410895000_glag009-B5","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.neurobiolaging.2003.09.001","article-title":"Synaptic slaughter in Alzheimer\u2019s disease","volume":"24","author":"Coleman","year":"2003","journal-title":"Neurobiol Aging."},{"key":"2026040408410895000_glag009-B6","doi-asserted-by":"publisher","first-page":"8740","DOI":"10.1073\/pnas.1206171109","article-title":"Critical role of soluble amyloid-beta for early hippocampal hyperactivity in a mouse model of Alzheimer\u2019s disease","volume":"109","author":"Busche","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026040408410895000_glag009-B7","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/nn.4163","article-title":"Decreased amyloid-beta and increased neuronal hyperactivity by immunotherapy in Alzheimer\u2019s models","volume":"18","author":"Busche","year":"2015","journal-title":"Nat Neurosci."},{"key":"2026040408410895000_glag009-B8","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/nature07456","article-title":"Neuroligins and neurexins link synaptic function to cognitive disease","volume":"455","author":"S\u00fcdhof","year":"2008","journal-title":"Nature"},{"key":"2026040408410895000_glag009-B9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.conb.2007.01.011","article-title":"Neurexin-neuroligin signaling in synapse development","volume":"17","author":"Craig","year":"2007","journal-title":"Curr Opin Neurobiol."},{"key":"2026040408410895000_glag009-B10","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3389\/fncel.2020.00281","article-title":"Synaptic organizers in Alzheimer\u2019s disease: a classification based on amyloid-beta sensitivity","volume":"14","author":"Lee","year":"2020","journal-title":"Front Cell Neurosci"},{"key":"2026040408410895000_glag009-B11","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1073\/pnas.96.3.1100","article-title":"Neuroligin 1 is a postsynaptic cell-adhesion molecule of excitatory synapses","volume":"96","author":"Song","year":"1999","journal-title":"Proc Natl Acad Sci USA."},{"key":"2026040408410895000_glag009-B12","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.neuron.2012.10.003","article-title":"Activity-dependent proteolytic cleavage of neuroligin-1","volume":"76","author":"Suzuki","year":"2012","journal-title":"Neuron"},{"key":"2026040408410895000_glag009-B13","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.neuron.2012.07.006","article-title":"Transsynaptic signaling by activity-dependent cleavage of neuroligin-1","volume":"76","author":"Peixoto","year":"2012","journal-title":"Neuron"},{"key":"2026040408410895000_glag009-B14","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1074\/mcp.M114.046813","article-title":"Multiplexed, quantitative workflow for sensitive biomarker discovery in plasma yields novel candidates for early myocardial injury","volume":"14","author":"Keshishian","year":"2015","journal-title":"Mol Cell Proteomics."},{"key":"2026040408410895000_glag009-B15","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1038\/nprot.2017.054","article-title":"Quantitative, multiplexed workflow for deep analysis of human blood plasma and biomarker discovery by mass spectrometry","volume":"12","author":"Keshishian","year":"2017","journal-title":"Nat Protoc."},{"key":"2026040408410895000_glag009-B16","doi-asserted-by":"publisher","first-page":"6956","DOI":"10.1038\/s41598-020-63255-6","article-title":"Neuroligin-1 is altered in the hippocampus of Alzheimer\u2019s disease patients and mouse models, and modulates the toxicity of amyloid-beta oligomers","volume":"10","author":"Dufort-Gervais","year":"2020","journal-title":"Sci Rep"},{"key":"2026040408410895000_glag009-B17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3389\/neuro.05.028.2009","article-title":"Diminished perisomatic GABAergic terminals on cortical neurons adjacent to amyloid plaques","volume":"3","author":"Garcia-Marin","year":"2009","journal-title":"Front Neuroanat"},{"key":"2026040408410895000_glag009-B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scisignal.abd8379","article-title":"Neuroligin-2 as a central organizer of inhibitory synapses in health and disease","volume":"13","author":"Ali","year":"2020","journal-title":"Sci Signal."},{"key":"2026040408410895000_glag009-B19","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","article-title":"Highly accurate blood test for Alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests","volume":"30","author":"Barth\u00e9lemy","year":"2024","journal-title":"Nat Med."},{"key":"2026040408410895000_glag009-B20","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/s1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurol"},{"key":"2026040408410895000_glag009-B21","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","article-title":"Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology","volume":"141","author":"Ashton","journal-title":"Acta Neuropathol"},{"key":"2026040408410895000_glag009-B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1084\/jem.20200861","article-title":"Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease","volume":"217","author":"Barth\u00e9lemy","year":"2020","journal-title":"J Exp Med."},{"key":"2026040408410895000_glag009-B23","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1590\/1806-9282.66.4.512","article-title":"Structural volume of hippocampus and Alzheimer\u2019s disease","volume":"66","author":"Balestrieri","year":"2020","journal-title":"Rev Assoc Med Bras"},{"key":"2026040408410895000_glag009-B24","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1074\/mcp.RA118.001290","article-title":"Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer\u2019s disease cerebrospinal fluid","volume":"18","author":"Lle\u00f3","year":"2019","journal-title":"Mol Cell Proteomics."},{"key":"2026040408410895000_glag009-B25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40478-021-01119-4","article-title":"Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers","volume":"9","author":"Camporesi","year":"2021","journal-title":"Acta Neuropathol Commun"},{"key":"2026040408410895000_glag009-B26","doi-asserted-by":"crossref","first-page":"103793","DOI":"10.1016\/j.ebiom.2021.103793","article-title":"Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry","volume":"75","author":"Camporesi","year":"2022","journal-title":"EBioMedicine"},{"key":"2026040408410895000_glag009-B27","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/s1474-4422(09)70016-x","article-title":"Matrix metalloproteinases and their multiple roles in neurodegenerative diseases","volume":"8","author":"Rosenberg","year":"2009","journal-title":"Lancet Neurol."},{"key":"2026040408410895000_glag009-B28","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1096\/fj.201700731R","article-title":"Declining levels of functionally specialized synaptic proteins in plasma neuronal exosomes with progression of Alzheimer\u2019s disease","volume":"32","author":"Goetzl","year":"2018","journal-title":"Faseb J."},{"key":"2026040408410895000_glag009-B29","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1093\/brain\/awad159","article-title":"The amyloid cascade hypothesis: an updated critical review","volume":"146","author":"Kepp","year":"2023","journal-title":"Brain."},{"key":"2026040408410895000_glag009-B30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41582-022-00749-z","article-title":"Synaptic degeneration in Alzheimer disease","volume":"19","author":"Tzioras","year":"2023","journal-title":"Nat Rev Neurol."},{"key":"2026040408410895000_glag009-B31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1212\/wnl.56.1.127","article-title":"Altered expression of synaptic proteins occurs early during progression of Alzheimer\u2019s disease","volume":"56","author":"Masliah","year":"2001","journal-title":"Neurology"},{"key":"2026040408410895000_glag009-B32","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1212\/01.wnl.0000260698.46517.8f","article-title":"Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment","volume":"68","author":"Scheff","year":"2007","journal-title":"Neurology"},{"key":"2026040408410895000_glag009-B33","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13195-015-0161-y","article-title":"Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer\u2019s disease","volume":"7","author":"Hellwig","year":"2015","journal-title":"Alzheimers Res Ther."},{"key":"2026040408410895000_glag009-B34","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13195-015-0124-3","article-title":"Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer\u2019s disease patients and healthy controls","volume":"7","author":"Kvartsberg","year":"2015","journal-title":"Alzheimers Res Ther"},{"key":"2026040408410895000_glag009-B35","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1750-1326-9-53","article-title":"SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer\u2019s disease","volume":"9","author":"Brinkmalm","year":"2014","journal-title":"Mol Neurodegener."},{"key":"2026040408410895000_glag009-B36","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.jalz.2015.05.012","article-title":"C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer\u2019s disease","volume":"11","author":"De Vos","year":"2015","journal-title":"Alzheimers Dement."},{"key":"2026040408410895000_glag009-B37","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1515\/cclm-2023-1434","article-title":"Blood-based biomarkers in Alzheimer\u2019s disease\u2014moving towards a new era of diagnostics","volume":"62","author":"Arslan","year":"2024","journal-title":"Clin Chem Lab Med"},{"key":"2026040408410895000_glag009-B38","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/alz.12790","article-title":"Relationship of serum beta-synuclein with blood biomarkers and brain atrophy","volume":"19","author":"Oeckl","year":"2023","journal-title":"Alzheimers Dement."},{"key":"2026040408410895000_glag009-B39","doi-asserted-by":"publisher","first-page":"5095","DOI":"10.1002\/alz.13103","article-title":"Higher plasma \u03b2-synuclein indicates early synaptic degeneration in Alzheimer\u2019s disease","volume":"19","author":"Oeckl","year":"2023","journal-title":"Alzheimers Dement."},{"key":"2026040408410895000_glag009-B40","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13195-022-01021-8","article-title":"Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer\u2019s disease","volume":"14","author":"Nilsson","year":"2022","journal-title":"Alzheimers Res Ther."},{"key":"2026040408410895000_glag009-B41","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1152\/physrev.00031.2020","article-title":"Fluid transport in the brain","volume":"102","author":"Rasmussen","year":"2022","journal-title":"Physiol Rev."},{"key":"2026040408410895000_glag009-B42","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/s1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"15","author":"Olsson","year":"2016","journal-title":"Lancet Neurol."},{"key":"2026040408410895000_glag009-B43","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.mcn.2018.12.004","article-title":"Fluid and PET biomarkers for amyloid pathology in Alzheimer\u2019s disease","volume":"97","author":"Cohen","year":"2019","journal-title":"Mol Cell Neurosci."},{"key":"2026040408410895000_glag009-B44","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/s1474-4422(22)00168-5","article-title":"Tau biomarkers in Alzheimer\u2019s disease: towards implementation in clinical practice and trials","volume":"21","author":"Ossenkoppele","year":"2022","journal-title":"Lancet Neurol."},{"key":"2026040408410895000_glag009-B45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13195-016-0208-8","article-title":"The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer\u2019s disease","volume":"8","author":"\u00d6hrfelt","year":"2016","journal-title":"Alzheimers Res Ther."},{"key":"2026040408410895000_glag009-B46","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/joim.12816","article-title":"Biomarkers for Alzheimer\u2019s disease: current status and prospects for the future","volume":"284","author":"Blennow","year":"2018","journal-title":"J Intern Med."},{"key":"2026040408410895000_glag009-B47","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41582-022-00665-2","article-title":"Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility","volume":"18","author":"Karikari","year":"2022","journal-title":"Nat Rev Neurol."}],"container-title":["The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/biomedgerontology\/advance-article-pdf\/doi\/10.1093\/gerona\/glag009\/66754805\/glag009.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/biomedgerontology\/article-pdf\/81\/4\/glag009\/66754805\/glag009.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/biomedgerontology\/article-pdf\/81\/4\/glag009\/66754805\/glag009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T12:41:12Z","timestamp":1775306472000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/biomedgerontology\/article\/doi\/10.1093\/gerona\/glag009\/8460837"}},"subtitle":[],"editor":[{"given":"Gustavo","family":"Duque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3,10]]}},"URL":"https:\/\/doi.org\/10.1093\/gerona\/glag009","relation":{},"ISSN":["1079-5006","1758-535X"],"issn-type":[{"value":"1079-5006","type":"print"},{"value":"1758-535X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,2,3]]},"article-number":"glag009"}}